Costs of the detection of metastases and follow-up examinations in cutaneous melanoma

Melanoma Research

Volumn 19, Issue 1, 2009, Pages 50-57

  Leiter, Ulrike ^a   Marghoob, Ashfaq A ^b   Lasithiotakis, Konstantinos ^a   Eigentler, Thomas K ^a   Meier, Friedegund ^a   Meisner, Christoph ^a   Garbe, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Costs; Follow up schedule; Melanoma; Recurrences

Indexed keywords

ABDOMINAL RADIOGRAPHY; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CUTANEOUS MELANOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOGRAPHY; EUROPE; FOLLOW UP; HEALTH CARE COST; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICARE; MELANOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REIMBURSEMENT; SKIN EXAMINATION; STRATEGIC PLANNING; THORAX RADIOGRAPHY; UNITED STATES;

COSTS AND COST ANALYSIS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FOLLOW-UP STUDIES; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 59549092794     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32831bc41c     Document Type: Article

References (32)

1. Garbe C. A rational approach to the follow-up of melanoma patients. Recent Results Cancer Res 2002; 160:205-215.
2. Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M, Sertoli MR, Rosso R. Stage I-II melanoma: the value of metastatic work-up. Oncology 1987; 44:87-89.
3. Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C. Position and recommendations of the malignant melanoma committee of the German society of dermatology on diagnosis, treatment and after-care of malignant melanoma of the skin. Status 1993/94. Hautarzt 1994; 45:285-291.
4. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6:608-621.
5. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21:520-529.
6. Huang CL, Provost N, Marghoob AA, Kopf AW, Levin L, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 1998; 39:451-463.
7. Provost N, Marghoob AA, Kopf AW, DeDavid M, Wasti Q, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. J Am Acad Dermatol 1997; 36(5Pt 1):711-720.
8. Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45:579-586.
9. Besseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Cost-effectiveness of surveillance of stage I melanoma: a retrospective appraisal based on a 10-year experience in a Dermatology Department in France. Dermatology. 1995; 191:199-203.
10. Hofmann U Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002; 87:151-157.
11. Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective? Anticancer Res 2000; 20 (3B):2193-2196.
12. Kleeberg UR. Wishful thinking, unicentric empiricism and the everyday world of the medical melanomologist. Melanoma Res 1997; 7 (Suppl 2): S143-S149.
13. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999; 86:2252-2258.
14. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19:3635-3648.
15. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18:3302-3317.
16. Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol 2002; 20:263-273.
17. Fleming JB, Cantor SB, Varma DG, Holst D, Feig BW, Hunt KK, et al. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer 2001; 92:863-868.
18. Ganz PA, Litwin MS. Prostate cancer: the price of early detection. J Clin Oncol 2001; 19:1587-1588.
19. Van den Hout WB, Van den Brink M, Stiggelbout AM, Van de V, Kievit J. Cost-effectiveness analysis of colorectal cancer treatments. Eur J Cancer 2002; 38:953-963.
20. Girgis A, Clarke P, Burton RC, Sanson-Fisher RW. Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen 1996; 3:47-53.
21. Tsao H, Rogers QS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol 1998; 38 (5 Pt 1): 669-680.
22. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 2003; 1:1.
23. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003; 97:1737-1745.
24. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer Stage IV Melanoma. J Clin Oncol 1999; 17:1891-1896.
25. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20 (3B):2203-2207.
26. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56: 338-344.
27. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, Hansson J. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19:824-831.
28. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 1997; 80:1052-1064.
29. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. J Am Med Assoc 1995; 274:1703-1705.
30. Saiag P. Recommendations for an effective follow-up strategy in melanoma patients should be tailored to the investigations performed during initial staging. J Clin Oncol 2003; 21:3706-3707.
31. Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, Larson S. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006; 13:525-532.
32. Hengge UR, Wallerand A, Stutzki A, Kockel N. Cost-effectiveness of reduced follow-up in malignant melanoma. J Dtsch Dermatol Ges 2007; 5:898-907.